Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.52 |
| ▸ | VCP | P55072 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | MPL | P40238 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208205 | 0.87 | AGER (0.59) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL19851004 | 0.87 | AGER (0.70) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7113308 | 0.85 | CYP1B1 (0.67) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL205448 | 0.83 | ALOX5 (0.65) | NPC1RAB9AMEN1KMT2ACYP1B1 | |
| SCHEMBL29276772 | 0.82 | AGER (0.75) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL28908960 | 0.80 | AGER (0.62) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16603960 | 0.79 | AGER (1.00) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL205404 | 0.79 | VCP (0.65) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL19851003 | 0.79 | CTRB1 (0.64) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7113187 | 0.79 | ALOX5 (0.65) | RAB9AMEN1KMT2AVCPALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220380-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | claimed |
| US-6586453-B2 | Useful in prophylaxis or treatment of thrombosis, angina, pectoris, cerebral infarction, myocardial/pulmonary infarction, intra-atrial thrombus in atrial fibrillation, diabetic complications, restenosis, and stroke | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | claimed |
| US-20010044545-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-22 | — | — | US | claimed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20030220380-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-6586453-B2 | Useful in prophylaxis or treatment of thrombosis, angina, pectoris, cerebral infarction, myocardial/pulmonary infarction, intra-atrial thrombus in atrial fibrillation, diabetic complications, restenosis, and stroke | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | disclosed |
| US-20010044545-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | AGER 3576/4885NPC1 62/4885RAB9A 1357/4885 |
| US-20010044545-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | AGER 439/4885NPC1 2395/4885RAB9A 2193/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | AGER 3576/4885NPC1 62/4885RAB9A 1357/4885 |
| US-20030220380-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | AGER 439/4885NPC1 2395/4885RAB9A 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.